



# BIO MEDICA LABORATORIES PVT. LTD.

## BOARD'S REPORT

To,  
The Members of  
**BIO MEDICA LABORATORIES PRIVATE LIMITED**

Your director's have pleasure in presenting the 09<sup>th</sup> Board's Report of your Company together with the Audited Statement of Accounts and the Auditors' Report of your company for the financial year ended, 31<sup>st</sup> March, 2024.

### **1. FINANCIAL HIGHLIGHTS**

The financial statements of the Company have been prepared in accordance with the Generally Accepted Accounting Principles in India (Indian GAAP). The financial highlights of your Company for the Financial Year ended 31<sup>st</sup> March, 2024 are summarized below:

**Rupees in thousands (except E.P.S.)**

Particulars	Current year	Previous Year
Revenue from Operations	1,52,493.58	1,62,281.78
Other Income	948.71	492.90
<b>Total Revenue</b>	<b>1,53,442.29</b>	<b>1,62,774.68</b>
Expenses		
a. Cost of Material Consumed	73,821.31	1,15,870.74
b. Purchases of Stock-in-Trade	-	-
c. Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	(7,123.44)	(1,189.24)
d. Employee benefit expenses	17,033.99	18,123.09
e. Financial cost	9,659.10	7,742.70
f. Depreciation and amortization expenses	11,099.64	4,966.77
g. Other Expense	13,256.21	12,383.95
<b>Total Expenses</b>	<b>1,17,746.81</b>	<b>1,57,898.01</b>
<b>Profit/(Loss) Before Tax</b>	<b>35,695.49</b>	<b>4,876.67</b>
Tax Expense		
Current Tax	10,218.38	1,257.07
Deferred Tax	(824.02)	21.01
<b>Profit/(Loss) for the period</b>	<b>26,301.13</b>	<b>3,598.59</b>

Board's Report of **BIO MEDICA LABORATORIES PRIVATE LIMITED**

Plot No. 254, Sector-F, Sanwer Road, Industrial Area, INDORE-452015 (MP) Email: bmlpl2014@gmail.com  
Plot No. 11B-11C, Sector-E, Sanwer Road, Industrial Area, INDORE-452015 (MP) bmlpl2022@gmail.com  
CIN: U24230MP2015PTC034576; Mobile No. 9827210008/7869595951/7999274343

## **2. STATE OF COMPANY'S AFFAIRS**

The highlights of the Company's performance are as under:

- Revenue from the operations in the year 2023-2024 is **Rs.1,52,493.58 Thousand**.
- The Company has earned profit after tax of **Rs. 26,301.13 Thousand** in the year 2023-2024 as compared to **Rs. 3,598.59 Thousand** in the year 2022-23.
- Total Paid-Up Share Capital of the Company Remains unchanged at **Rs.10,00,000/-**.
- Basic Earnings per Share (EPS) is **Rs. 263.14/-** as compared to **Rs. 35.99/-** per share as previous year.

## **3. DIVIDEND**

Your Directors have considered it financially prudent in the long-term interests of the Company to reinvest the profits into the business of the Company to build a strong reserve base and grow the business of the Company. No final dividend has therefore been recommended for the year ended March 31, 2024.

## **4. DIRECTORS' RESPONSIBILITY STATEMENT**

Pursuant to Section 134(5) of the Companies Act, 2013, the board of directors, to the best of their knowledge and ability, confirm that:

- a) In the preparation of the annual accounts for the year ended March 31, 2024, the applicable accounting standards read with requirements set out under Schedule III to the Act, have been followed and there are no material departures from the same;
- b) The Directors have selected such accounting policies and applied them consistently and made judgments and estimates that are reasonable and prudent so as to give a true and fair view of the state of affairs of the Company as at March 31, 2024 and of the profit of the Company for the year ended on that date;
- c) The Directors have taken proper and sufficient care for the maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting fraud and other irregularities;
- d) The Directors have prepared the annual accounts on a 'going concern' basis;
- e) The Directors have laid down internal financial controls to be followed by the Company and that such internal financial controls are adequate and are operating effectively; and
- f) The Directors have devised proper systems to ensure compliance with the provisions of all applicable laws and that such systems are adequate and operating effectively.



## 5. INTERNAL FINANCIAL CONTROL

Based on the framework of internal financial controls and compliance systems established and maintained by the Company, work performed by the statutory auditors and external consultants and the reviews performed by management and the relevant board committees, the board is of the opinion that the Company's internal financial controls were adequate and effective during the financial year 2023-2024.

## 6. BOARD OF DIRECTORS, KEY MANAGERIAL PERSONNEL, AND CHANGES THEREOF

According to the provisions of Companies Act, 2013 read with Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014, the Board of Directors of the Company is duly constituted. Further, there is no change in the composition of the Board of Directors during the year. Furthermore, None of the Directors of the Company are disqualified under section 164 of the Companies Act, 2013 from being appointed as a Director. The existing Directors of the Company are:

S. No.	Director Name	DIN	Designation
1.	Shri Mukesh Mehta	03187420	Director
2.	Shri Pradeep Mehta	07254802	Director

## 7. MEETINGS OF THE BOARD OF DIRECTORS

The following Meetings of the Board of Directors were held during the Financial Year 2023-24:

S.No.	Date of Meeting	Board Strength	No. of Directors Present
1	12/04/2023	2	2
2	31/07/2023	2	2
3	02/09/2023	2	2
4	28/10/2023	2	2
5	09/11/2023	2	2
6	18/01/2024	2	2

## 8. STATUTORY AUDITORS'

Pursuant to the provisions of Section 139 of the Act and the rules framed thereunder, the Board of Directors had appointed **Akshay Vijawat & Co. Chartered Accountants (FRN: 023175C)**, to hold office for 5 years but due to pre-occupation the statutory auditor had resigned on 03<sup>rd</sup> August, 2024 and the casual vacancy caused is duly filled up by appointment of **M/s Satyanarayan Goyal & Co LLP (FRN: 006636C/C400333), Chartered Accountants**, Indore in the duly held board meeting on 03<sup>rd</sup> August, 2024 which was further confirmed by the Shareholders of the Company in the duly held Extra Ordinary General Meeting on 14<sup>th</sup> August, 2024 to hold office as Statutory Auditor of the company till the ensuing Annual General Meeting of the Company to be held in the year 2024.

Pursuant to the provisions of Section 139 of the Act and the rules framed thereunder, the Board of Directors has now recommended the appointment of, **M/s Satyanarayan Goyal & Co LLP (FRN: 006636C/C400333), Chartered Accountants**, to hold office for the period of 5 years, till the conclusion of the Annual General Meeting to be held in the year 2029. **M/s Satyanarayan Goyal & Co LLP (FRN: 006636C/C400333), Chartered Accountants**, have given their consent for appointment as the Statutory Auditors of the Company.

#### **9. AUDITORS' REPORT**

The Board has duly reviewed the Statutory Auditors' Report on the Financial Statements of the Company. There are no qualifications or adverse remarks in the Auditors' Report which require any clarification/ explanation. The Notes on financial statements are self-explanatory and needs no further explanation. Further the Auditors' Report for the financial year ended, 31<sup>st</sup> March, 2024 is annexed herewith for your kind perusal and information.

#### **10. TRANSFER OF UNCLAIMED DIVIDEND TO INVESTOR EDUCATION AND PROTECTION FUND**

The provisions of Section 125(2) of the Companies Act, 2013 do not apply as there was no dividend declared and paid last year.

#### **11. TRANSFER TO RESERVES**

No Amount is transferred to the general reserve, however an amount of **Rs. 26,313.76 thousand** is transferred as surplus from profit and loss account.

#### **12. MATERIAL CHANGES AND COMMITMENT IF ANY AFFECTING THE FINANCIAL POSITION OF THE COMPANY OCCURRED BETWEEN THE END OF THE FINANCIAL YEAR TO WHICH THIS FINANCIAL STATEMENTS RELATE AND THE DATE OF THE REPORT**

No material changes and commitments affecting the financial position of the Company occurred during the financial year to which these financial statements relate.

#### **13. CONSERVATION OF ENERGY, TECHNOLOGY ABSORPTION, FOREIGN EXCHANGE EARNINGS AND OUTGO**

##### **A. CONSERVATION OF ENERGY:**

##### **a. The steps taken or impact on conservation of energy:-**

The company is putting continues efforts to reduce the consumption of energy and maximum possible saving of energy.

##### **b. The steps taken by the company for utilizing alternate sources of energy:-**

The Company has used alternate source of energy, whenever and to the extent possible

##### **c. The capital investment on energy conservation equipment:- NIL**

**B. TECHNOLOGY ABSORPTION:**

a. The effort made towards technology absorption-

No specific activities have been done by the Company.

b. The benefits derived like product improvement, cost reduction, product development or import substitution-

No specific activity has been done by the Company

c. In case of imported technology (imported during the last three years reckoned from the beginning of the financial year:- NA

d. The expenditure incurred on Research & Development.- NIL

**C. FOREIGN EXCHANGE EARNINGS AND OUTGO:**

There are no Foreign Exchange earnings and outgoings were taken place during the financial year as required by Companies (Accounts) Rules, 2014.

**14. STATEMENT CONCERNING DEVELOPMENT AND IMPLEMENTATION OF RISK MANAGEMENT POLICY OF THE COMPANY**

The Company does not have any Risk Management Policy as the element of risk threatening the Company's existence is very minimal.

**15. DETAILS OF POLICY DEVELOPED AND IMPLEMENTED BY THE COMPANY ON ITS CORPORATE SOCIAL RESPONSIBILITY INITIATIVES**

The Company has not developed and implemented any Corporate Social Responsibility initiatives as the said provisions are not applicable for this year 2023-24.

**16. DETAILS OF SIGNIFICANT AND MATERIAL ORDERS PASSED BY THE REGULATORS OR COURTS OR TRIBUNALS IMPACTING THE GOING CONCERN STATUS AND COMPANY'S OPERATION IN FUTURE**

There are no significant and material orders passed by the Regulators or Courts or Tribunals impacting the going concern status and company's operations in future.



**17. PARTICULARS OF LOANS, GUARANTEES OR INVESTMENTS MADE UNDER SECTION 186 OF THE COMPANIES ACT, 2013**

The Company has not granted loans or not given any guarantee nor made any investments under section 186 of the Companies Act, 2013 for the financial year ended 31<sup>st</sup> March 2024.

**18. PARTICULARS OF CONTRACTS OR ARRANGEMENTS MADE WITH RELATED PARTIES**

The Contract/arrangement entered into with the related parties for the year under review were in ordinary course of business and on arm's length basis and there are some material transactions which are to be reported under section 188 (1) of the Companies Act, 2013, the disclosure of the same is given as an annexure in AOC-2.

**19. FORMAL ANNUAL EVALUATION**

The statement indicating the manner of formal Annual Evaluation by the Board of its own performance and that of its committees and individual directors, pursuant to the clause 134 (3) (p) of the Companies Act, 2013, read with Rule 8 of Companies (Accounts) Rules, 2014, is not applicable to the Company.

**20. INDEPENDENT DIRECTOR**

The provisions of section 149 of the Companies Act, 2013 read with relevant Rules made thereunder are not applicable to the Company.

**21. SUBSIDIARIES, JOINT VENTURES AND ASSOCIATE COMPANIES**

The Company does not have any Subsidiary, Associate or Joint venture.

**22. REPORTING OF FRAUDS BY STATUTORY AUDITORS**

There was no fraud in the Company, which was required to be reported by the Statutory Auditors of the Company under sub section (12) of section 143 of the Companies Act, 2013.

**23. ACCEPTANCE OF LOANS FROM DIRECTORS AND THEIR RELATIVES**

The Company has taken any certain unsecured loan from the Directors or their relatives during the year, details of the same is duly provided under Note No. 7 of Audited Financial Statements of the Current Financial Year 2023-24.

**24. SECRETARIAL AUDIT REPORT**

The provisions of Section 204 of the Companies Act, 2013 for the appointment of Secretarial Auditor are not applicable to the Company.

**25. DEPOSITS**

The Company has not accepted any deposit during the year under review.

**26. VOTING RIGHTS OF EMPLOYEES:**

During the year under review the company has not given loan to any employee for purchase of its own shares as per section 67 (3) (c) of Companies Act, 2013. Therefore, the company is not required to made disclosure as per rule 6 (4) of Companies (Share Capital and Debentures) Rules, 2014.

**27. DISCLOSURE REGARDING ISSUE OF SWEAT EQUITY SHARES:**

The Company has not issued sweat equity shares pursuant to provisions of Section 54 read with Rule 8 of Companies (Share Capital and Debenture Rules, 2014) during the Financial Year.

**28. DISCLOSURE REGARDING ISSUE OF EMPLOYEE STOCK OPTIONS:**

The Company does not have issued shares under employee's stock options scheme pursuant to provisions of Section Rule 12(9) of Companies (Share Capital and Debenture Rules, 2014). So, the question does not arise about voting rights not exercised by employee.

**29. MAINTENANCE OF COST RECORDS AS PER SUB SECTION (1) OF SECTION 148 OF THE ACT**

The provisions of section 148(1) of the Companies Act, 2013, for the maintenance of the cost records are not applicable to the Company, as the maintenance of Cost Records has not been specified by the Central Government under sub section (1) of the Section 148 of the Act, in respect of the activities carried on by the Company.

**30. PREVENTION OF SEXUAL HARASSMENT AT WORKPLACE**

The Company is committed to provide a safe and conducive work environment to its employees. During the year under review.

Your Directors further state that during the year under review, there were no cases filed pursuant to the Sexual Harassment of Women at Workplace (Prevention, Prohibition and Redressal) Act, 2013.

**31. PARTICULARS OF EMPLOYEES:**

Your Company is a Private Limited Company; hence the provisions of section 197(12) of Companies Act, 2013 read with Rule 5(1) of the Companies (Appointment and Remuneration of Managerial Personnel) Rules, 2014 is not applicable to the Company.

**32. THE DETAILS OF APPLICATION MADE OR ANY PROCEEDING PENDING UNDER THE INSOLVENCY AND BANKRUPTCY CODE, 2016 (31 OF 2016) DURING THE YEAR ALONG WITH THEIR STATUS AS AT THE END OF THE FINANCIAL YEAR.**

• **Details of Application Filed Against the Company During the Year under review:**

Stakeholders may please note that neither any application is filed nor proceeding is pending against the company under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year under review.

• **Details of Application Filed by the Company During the Year under review:**

Stakeholders may please note that neither any application is filed by the company under the Insolvency and Bankruptcy Code, 2016 (31 of 2016) during the year under review.

**33. ACKNOWLEDGEMENT**

Your Directors wish to express their grateful appreciation to the continued co-operation received from the Banks, Government Authorities, Customers, Vendors and Shareholders during the year under review. Your Directors also wish to place on record their deep sense of appreciation for the committed service of the Executives, staff and Workers of the Company.

**//By and on behalf of Board of Director of//**

**Bio Medica Laboratories Private Limited**



**Mukesh Mehta**

Director

**DIN: 03187420**



**Pradeep Mehta**

Director

**DIN: 07254802**



**DATE: 7<sup>th</sup> September, 2024**

**PLACE: Indore**





## BIO MEDICA LABORATORIES PVT. LTD.

### FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis:

S. No.	Particulars	Details
(a)	Name (s) of the related party & nature of relationship	Nil
(b)	Nature of contracts/arrangements/transaction	Nil
(c)	Duration of the contracts/arrangements/transaction	Nil
(d)	Salient terms of the contracts or arrangements or transaction including the value, if any	Nil
(e)	Justification for entering into such contracts or arrangements or transactions'	Nil
(f)	Date(s) of approval by the Board	Nil
(g)	Amount paid as advances, if any	Nil
(h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	Nil


2. Details of material contracts or arrangements or transactions at Arm's length basis:

S.No.	Particulars	Details	Details	Details	Details	Details	Details	Details
(a)	Name (s) of the related party &	Hospara Healthcare	Tara Mehta	Garima Mehta	Anju Mehta	Lokesh Mehta	Bio Medica Parentals	Sears Phytochem Pvt Ltd
(b)	Nature of relationship	Sister Concern	Director's Relative	Director's Relative	Director's Relative	Director's Relative	Sister Concern	Sister Concern
(c)	Nature of contracts/arrangements/transaction	Sales	Salary	Salary	Salary	Salary	Supervision Charges Paid	Purchases
(d)	Duration of the contracts/arrangements/transaction	-	-	-	-	-	-	-
(e)	Salient terms of the contracts or arrangements or transaction including the value, if any	-	-	-	-	-	-	-
(f)	Date(s) of approval by the Board	12/04/2023	12/04/2023	12/04/2023	12/04/2023	12/04/2023	12/04/2023	12/04/2023
(g)	Amount paid as advances, if any	-	-	-	-	-	-	-

//By and on behalf of Board of Director of//

Bio Medica Laboratories Private Limited

(CIN: U24230MP2015PTC034576)



Mukesh Mehta

Director

DIN: 03187420



Pradeep Mehta

Director

DIN: 07254802

DATE: 07<sup>th</sup> September, 2024

PLACE: Indore





## BIO MEDICA LABORATORIES PVT. LTD.

### LIST OF DIRECTORS

AS ON 31<sup>ST</sup> MARCH, 2024

Sr. No.	Name	DIN	Address	Designation
1	Mukesh Mehta	03187420	64-65 ShahidHemu Colony Near KamlaNeharuDharmshalaKilaMaidan RoadIndore( M.P) India452015	Director
2	Pradeep Mehta	07254802	64-65 ShahidHemu Colony KilaMaidan RoadIndore (M.P) India452015	Director

//By and on behalf of Board of Director of//  
Bio Medica Laboratories Private Limited  
(CIN: U24230MP2015PTC034576)

**Mukesh Mehta**  
Director  
DIN: 03187420

**Pradeep Mehta**  
Director  
DIN: 07254802



**DATE: 7<sup>th</sup> September, 2024**  
**PLACE: Indore**





## BIO MEDICA LABORATORIES PVT. LTD.

### LIST OF SHAREHOLDERS

AS ON 31<sup>st</sup> MARCH, 2024

S.No	Shareholder's Name	Father's /Husband's Name	Address	No. Of Shares Held
1	Mukesh Mehta	Lokesh Mehta	64-65 ShahidHemu Colony Near KamlaNeharuDharmshalaKilaMaidan Road Indore( M.P) India 452015	50,000
2	Pradeep Mehta	Lokesh Mehta	64-65 ShahidHemu Colony KilaMaidan Road Indore (M.P) India 452015	50,000
TOTAL				1,00,000

//By and on behalf of Board of Director of//  
Bio Medica Laboratories Private Limited  
(CIN:U24230MP2015PTC034576)

  
**Mukesh Mehta**  
Director  
DIN: 03187420

  
**Pradeep Mehta**  
Director  
DIN: 07254802



DATE: 7<sup>th</sup> September, 2024  
PLACE: Indore



## BIO MEDICA LABORATORIES PVT. LTD.

### FORM NO. AOC -2

(Pursuant to clause (h) of sub-section (3) of section 134 of the Act and Rule 8(2) of the Companies (Accounts) Rules, 2014)

Form for Disclosure of particulars of contracts/arrangements entered into by the company with related parties referred to in sub section (1) of section 188 of the Companies Act, 2013 including certain arm's length transaction under third proviso thereto.

1. Details of contracts or arrangements or transactions not at Arm's length basis:

S. No.	Particulars	Details
(a)	Name (s) of the related party & nature of relationship	Nil
(b)	Nature of contracts/arrangements/transaction	Nil
(c)	Duration of the contracts/arrangements/transaction	Nil
(d)	Salient terms of the contracts or arrangements or transaction including the value, if any	Nil
(e)	Justification for entering into such contracts or arrangements or transactions	Nil
(f)	Date(s) of approval by the Board	Nil
(g)	Amount paid as advances, if any	Nil
(h)	Date on which the special resolution was passed in General meeting as required under first proviso to section 188	Nil

2. Details of material contracts or arrangements or transactions at Arm's length basis:

S.No.	Particulars	Details	Details	Details	Details	Details	Details	Details
(a)	Name (s) of the related party &	Hospara Healthcare	Tara Mehta	Garima Mehta	Anju Mehta	Lokesh Mehta	Bio Medica Parentals	Sears Phytochem Pvt Ltd
(b)	Nature of relationship	Sister Concern	Director's Relative	Director's Relative	Director's Relative	Director's Relative	Sister Concern	Sister Concern
(c)	Nature of contracts/arrangements/transaction	Sales	Salary	Salary	Salary	Salary	Supervision Charges Paid	Purchases
(d)	Duration of the contracts/arrangements/transaction	-	-	-	-	-	-	-
(e)	Salient terms of the contracts or arrangements or transaction including the value, if any	-	-	-	-	-	-	-
(f)	Date(s) of approval by the Board	12/04/2023	12/04/2023	12/04/2023	12/04/2023	12/04/2023	12/04/2023	12/04/2023
(g)	Amount paid as advances, if any	-	-	-	-	-	-	-

//By and on behalf of Board of Director of//

Bio Medica Laboratories Private Limited

(CIN: U24230MP2015PTC034576)



Mukesh Mehta

Director

DIN: 03187420



Pradeep Mehta

Director

DIN: 07254802

DATE: 07<sup>th</sup> September, 2024

PLACE: Indore







## INDEPENDENT AUDITOR'S REPORT

To

The Members of,  
**BIO MEDICA LABORATORIES PRIVATE LIMITED**  
PLOT-254, SECTOR-F SANWER ROAD,  
Indore, (M.P.) - 452015

Report on the Audit of the Financial Statements

### Opinion

We have audited the accompanying Financial Statements of **BIO MEDICA LABORATORIES PRIVATE LIMITED** ("the Company"), which comprise the Balance Sheet as at March 31, 2024, the Statement of Profit and Loss, cash flow for the year ended on 31.03.2024, and notes to the financial statements including a summary of significant accounting policies and other explanatory information (hereinafter referred to as "Financial Statements").

In our opinion and to the best of our information and according to the explanations given to us, the aforesaid Financial Statements give the information required by the Companies Act, 2013 ("the Act") in the manner so required and give a true and fair view in conformity with the Accounting Standards prescribed under section 133 of the Act read with the Companies (Accounting Standards) Rules, 2006, as amended ("Accounting Standards") and other accounting principles generally accepted in India, of the state of affairs of the Company as at March 31, 2024, its profit/loss and cash flow for the year ended on that date.

### Basis for Opinion

We conducted our audit of the Financial Statements in accordance with the Standards on Auditing specified under section 143(10) of the Act (SAs). Our responsibilities under those Standards are further described in the Auditor's Responsibility for the Audit of the Financial Statements section of our report. We are independent of the Company in accordance with the Code of Ethics issued by the Institute of Chartered Accountants of India (ICAI) together with the ethical requirements that are relevant to our audit of the Financial Statements under the provisions of the Act and the Rules made thereunder, and we have fulfilled our other ethical responsibilities in accordance with these requirements and the ICAI's Code of Ethics. We believe that the audit evidence obtained by us is sufficient and appropriate to provide a basis for our audit opinion on the Financial Statements.

### Other Information - Board of Directors' Report

The Company's Board of Directors is responsible for the preparation of the other information and preparation of its Board's Report. The other information comprises various information required under Section 134(3) of the Companies Act, 2013. However, our opinion on the financial statements does not cover the other information and we do not express any form of assurance conclusion thereon.





In connection with our audit of the Financial Statements, our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained during the course of our audit or otherwise appears to be materially misstated. If, based on the work we have performed, we conclude that there is no material misstatement of this other information; we are required to report that fact.

We have nothing to report in this regard.

### **Management's Responsibility for the Financial Statements**

The Company's Board of Directors is responsible for the matters stated in section 134(5) of the Act with respect to the preparation of these Financial Statements that give a true and fair view of the financial position, financial performance and cash flows in accordance with the Accounting Standards and other accounting principles generally accepted in India. This responsibility also includes maintenance of adequate accounting records in accordance with the provisions of the Act for safeguarding the assets of the Company and for preventing and detecting frauds and other irregularities; selection and application of appropriate accounting policies; making judgments and estimates that are reasonable and prudent; and design, implementation and maintenance of adequate internal financial controls, that were operating effectively for ensuring the accuracy and completeness of the accounting records, relevant to the preparation and presentation of the financial statement that give a true and fair view and are free from material misstatement, whether due to fraud or error.

In preparing the Financial Statements, management is responsible for assessing the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless management either intends to liquidate the Company or to cease operations, or has no realistic alternative but to do so. Those Board of Directors are also responsible for overseeing the Company's financial reporting process.

### **Auditor's Responsibility for the Audit of the Financial Statements**

Our objectives are to obtain reasonable assurance about whether the Financial Statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditor's report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with SAs will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these Financial Statements.

As part of an audit in accordance with SAs, we exercise professional judgment and maintain professional skepticism throughout the audit. We also:

- Identify and assess the risks of material misstatement of the Financial Statements, whether due to fraud or error, design and perform audit procedures responsive to those risks, and obtain audit evidence that is sufficient and appropriate to provide a basis for our opinion. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control.

For Bio-Medica Laboratories Pvt. Ltd. For Bio-Medica Laboratories Pvt. Ltd.

  
Director.



Director.





- Obtain an understanding of internal financial control relevant to the audit in order to design audit procedures that are appropriate in the circumstances but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control systems.
- Evaluate the appropriateness of accounting policies used and the reasonableness of accounting estimates and related disclosures made by the management.
- Conclude on the appropriateness of management's use of the going concern basis of accounting and, based on the audit evidence obtained, whether a material uncertainty exists related to events or conditions that may cast significant doubt on the Company's ability to continue as a going concern. If we conclude that a material uncertainty exists, we are required to draw attention in our auditor's report to the related disclosures in the Financial Statements or, if such disclosures are inadequate, to modify our opinion. Our conclusions are based on the audit evidence obtained up to the date of our auditor's report. However, future events or conditions may cause the Company to cease to continue as a going concern.
- Evaluate the overall presentation, structure and content of the Financial Statements, including the disclosures, and whether the Financial Statements represent the underlying transactions and events in a manner that achieves fair presentation.

Materiality is the magnitude of misstatements in the Financial Statements that, individually or in aggregate, makes it probable that the economic decisions of a reasonably knowledgeable user of the Financial Statements may be influenced. We consider quantitative materiality and qualitative factors in (i) planning the scope of our audit work and in evaluating the results of our work; and (ii) to evaluate the effect of any identified misstatements in the Financial Statements.

We communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit and significant audit findings, including any significant deficiencies in internal control that we identify during our audit.

We also provide those charged with governance with a statement that we have complied with relevant ethical requirements regarding independence, and to communicate with them all relationships and other matters that may reasonably be thought to bear on our independence, and where applicable, related safeguards.

#### Report on Other Legal and Regulatory Requirements

1. As required by the Companies (Auditor's Report) Order, 2020 ("the Order") issued by the Central Government in terms of Section 143(11) of the Act, are **not applicable** to the Company.
2. As required by Section 143(3) of the Act, based on our audit, we report that:
  - A. We have sought and obtained all the information and explanations which to the best of our knowledge and belief were necessary for the purposes of our audit.
  - B. In our opinion, proper books of account as required by law have been kept by the Company so far as it appears from our examination of those books.

For Bio-Medica Laboratories Pvt. Ltd.

Director.

For Bio-Medica Laboratories Pvt. Ltd.

Director.





- C. The Balance Sheet, the Statement of Profit and Loss, Cash Flow Statement dealt with by this Report are in agreement with the relevant books of account.
- D. In our opinion, the aforesaid Financial Statements comply with the Accounting Standards specified under Section 133 of the Act.
- E. On the basis of the written representations received from the directors as on August 10<sup>th</sup>, 2024 taken on record by the Board of Directors, none of the directors is disqualified as on March 31, 2024 from being appointed as a director in terms of Section 164(2) of the Act.
- F. With respect to the adequacy of the internal financial controls over financial reporting of the Company and the operating effectiveness of such controls is **not applicable** to the Company.
- G. With respect to the other matters to be included in the Auditor's Report in accordance with Rule 11 of the Companies (Audit and Auditors) Rules, 2014, as amended in our opinion and to the best of our information and according to the explanations given to us:-
- a) The Company does not have any pending litigations which would impact its financial position.
  - b) The Company did not have any long-term contracts including derivative contracts for which there were any material foreseeable losses.
  - c) There were no amounts which were required to be transferred to the Investor Education and Protection Fund by the Company during the year ended 31<sup>st</sup> March 2024.
  - d)
    - i. The management has represented that, to the best of its knowledge and belief, no funds have been advanced or loaned or invested (either from borrowed funds or share premium or any other sources or kind of funds) by the Company to or in any other persons or entities, including foreign entities ("Intermediaries"), with the understanding, whether recorded in writing or otherwise, that the Intermediary shall:
      - directly or indirectly lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Company.
      - provide any guarantee, security or the like to or on behalf of the Ultimate Beneficiaries.
    - ii. The management has represented, that, to the best of its knowledge and belief, no funds have been received by the Company from any persons or entities, including foreign entities ("Funding Parties"), with the

For Bio-Medica Laboratories Pvt. Ltd. For Bio-Medica Laboratories Pvt. Ltd.

  
Director.



Director.



understanding, whether recorded in writing or otherwise, that the Company shall:

- directly or indirectly, lend or invest in other persons or entities identified in any manner whatsoever ("Ultimate Beneficiaries") by or on behalf of the Funding Party or
  - provide any guarantee, security or the like from or on behalf of the Ultimate Beneficiaries; and
- iii. Based on such audit procedures as considered reasonable and appropriate in the circumstances, nothing has come to our notice that has caused us to believe that the representations under subclause (d) (i) and (d) (ii) contain any material mis-statement.
- e) The Company has not paid any dividend during the year and hence, compliance with Section 123 of the Act is not applicable.
- f) Based on our examination which included test checks, the company has used an accounting software for maintaining its books of account which has a feature of recording audit trail (edit log) facility and the same has been operated throughout the year for all relevant transactions recorded in the software. Further, during the course of our audit we did not come across any instance of audit trail feature being tampered with.

As proviso to Rule 3(1) of the Companies (Accounts) Rules, 2014 is applicable from April 1, 2024, reporting under Rule 11(g) of the Companies (Audit and Auditors) Rules, 2014 on preservation of audit trail as per the statutory requirements for record retention is not applicable for the financial year ended March 31, 2024.

H. With respect to the other matters to be included in the Auditor's Report in accordance with the requirements of section 197(16) of the Act, in our opinion and to the best of our information and according to the explanations given to us, since the company is a private company, provision of section 197 of the Companies Act, 2013 is not applicable to the Company.

For: SATYANARAYAN GOYAL & CO LLP

Chartered Accountants

FRN: 006636C/C46000

CA Prabhakar Goyal (Partner)  
MRN: 429700

UDIN: 24429700BKQNM4582

Place: Indore

Date: 22-08-2024

For Bio-Medica Laboratories Pvt. Ltd.

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.



Director.



NOTES TO THE FINANCIAL STATEMENT FOR THE YEAR ENDED 31.03.2024

**1. CORPORATE INFORMATION**

Bio Medica Laboratories Private Limited is a private Company, limited by share domiciled in India and incorporated vide Reg. No. U24230MP2015PTC034576 under the provisions of Companies Act 2013 engaged in the business of operating a lab and manufacture products for others on a license or contract basis, whether in India or elsewhere. This includes importing, exporting, refining, formulating, buying, selling, and distributing pharmaceuticals and related products. Engage in business as chemists, druggists, buyers, sellers, agents, distributors, and stockists. Handle all types of medicines, including antibiotics, ayurvedic, allopathic, homeopathic, and other pharmaceuticals. This also includes medicines for humans and animals, vaccines, and health-related products.

**2. SIGNIFICANT ACCOUNTING POLICIES**

**2.1 STATEMENT OF COMPLIANCE**

These Financial Statements have been prepared in accordance with generally accepted accounting principles and specified standards in India under the historical cost convention on accrual basis in accordance with the provisions of section 133 of the Companies Act, 2013 read with rule 7 of Companies (Accounts) Rules 2014.

**2.2 BASIS OF PREPARATION**

The enterprise is a going concern and is expected to continue and grow from year to year.

These financial statements have been prepared under historical cost convention and on accrual basis, as explained in the accounting policies mentioned below.

All assets and liabilities have been classified as current or non current as per the Company's normal operating cycle and other criteria set out in the Schedule III to the Companies Act, 2013. Based on the nature of products and the time between acquisition of assets for processing and their realisation in cash and cash equivalents, the Company has ascertained its operating cycle as 12 months for the purpose of current/non current classification of assets and liabilities.

The financial statements including notes thereon are presented in Indian Rupees ("Rupees" or "INR"), which is the Company's functional and presentation currency. All amounts disclosed in the financial statements including notes thereon have been rounded off to the nearest thousands of Rupees as per the requirement of Schedule III to the Act, unless stated otherwise.

**2.3 USE OF ESTIMATES, JUDGMENTS AND ASSUMPTIONS**

The preparation of financial statements in conformity with Indian GAAPs requires the management to make judgement, estimates and assumptions that affect the reported amount of revenue, expenses, assets and liabilities at the end of reporting date. Actual results may differ from these estimates. Estimates and underlying assumptions are reviewed on an ongoing basis. Although these estimates are based on the management's best knowledge of the current events and actions, uncertainty about these assumptions and estimates could result in the outcomes requiring a material adjustment to the carrying amounts of assets or liabilities in future periods.

Significant areas of estimation, uncertainty, and critical judgements in applying accounting policies that have significant effect amount recognized in the financial statements are:

- i. Recognition and measurement of provision and contingencies.
- ii. Depreciation and useful lives of Property, plant, and equipment.
- iii. Recognition of deferred tax.
- iv. Income Taxes.

**2.4 INVENTORIES**

Inventories are valued at the lower of landed cost or net realizable value, in accordance with the relevant Accounting Standard (AS 2 - Valuation of Inventories). The cost of inventory generally comprises the cost of purchase, the cost of conversion, and other costs incurred in bringing the inventory to their present location and condition.

1. **Landed Cost:** Includes the cost of purchase plus additional costs such as freight, handling, and other costs directly attributable to the acquisition of the inventory.

2. **Net Realizable Value:** The estimated selling price in the ordinary course of business, less the estimated costs of completion and the estimated costs necessary to make the sale.

This method ensures that inventories are not overstated in the financial statements and reflects the true value of the inventories held by the company.



For Bio-Medica Laboratories Pvt. Ltd.

*Kuldeep*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.

## **2.5 REVENUE RECOGNITION**

### **a. Revenue from operations:**

i. Revenue from the sale of goods is recognised when the control of the goods has been passed to the customer as per the terms of agreement and there is no continuing effective control or managerial involvement with the goods.

ii. Other operational revenue represents income earned from the activities incidental to the business and is recognized when the performance obligation is satisfied and right to receive the income is established as per the terms of the contract.

b. Interest income is accounted on an accrual basis at effective interest rate. Interest on delayed payment and forfeiture income are accounted based upon underlying agreements with customers.

c. Dividend income, if any, is recognised in profit or loss on the date on which the company's right to receive payment is established.

## **2.6 PROPERTY, PLANT & EQUIPMENT**

### **a. Measurement and recognition:**

An item of property, plant and equipment that qualifies as an asset is measured on initial recognition at cost.

Following initial recognition, items of property, plant and equipment are carried at its cost less accumulated depreciation and accumulated impairment losses, if any. The cost of an item of property, plant, and equipment comprises of its purchase price including import duties and other non-refundable purchase taxes or levies, directly attributable cost of bringing the asset to its working condition for its intended use and the initial estimate of decommissioning, restoration and similar liabilities, if any.

Subsequent expenditure is capitalised only if it is probable that the future economic benefits associated with the expenditure will flow to the company.

### **b. Depreciation:**

Depreciation is provided using written down method as specified in Schedule II to the Companies Act, 2013 or based on technical estimates. Depreciation on assets acquired/ disposed off during the year is provided on pro-rata basis with reference to the date of addition/ disposal.

### **c. De-recognition:**

An item of property, plant and equipment is derecognized upon disposal or when no future economic benefits are expected to arise from continued use of the asset. Any gain or loss arising on the disposal or retirement of property, plant and equipment is determined as the difference between the sale proceeds and the carrying amount of the assets and is recognized in Statement of Profit and Loss.

## **2.7 FOREIGN CURRENCY TRANSACTIONS AND TRANSLATIONS :-**

All transactions in foreign currency are recorded at the rates of exchange prevailing on the dates when the relevant transaction takes place. Monetary assets and liabilities in foreign currency, outstanding at the close of the year are converted into Indian currency at the prevailing exchange rates on the date of balance sheet. The resultant gain or loss is charged to the statement of profit and loss.

## **2.8 EMPLOYEE BENEFITS**

Retirement benefits in the form of Provident Fund & Other Fund are paid & charged to the Statement of Profit and Loss for the year when contributions to the respective Funds are due.

Gratuity liability under the Payment of Gratuity Act is paid & charged to the Statement of Profit and Loss for the year.

## **2.9 BORROWING COSTS**

Borrowing costs, if any, directly attributable to the acquisition, construction or production of an asset that necessarily takes a substantial period of time to get ready for its intended use or sale are capitalized, if any. All other borrowing costs are treated as expense in the period in which they are incurred.

## **2.10 TAXATION**

The income tax expense or credit for the period is the tax payable on the current period's taxable income based on the applicable income tax rate for each jurisdiction adjusted by changes in deferred tax assets and liabilities attributable to temporary differences and to unused tax losses.


### **a. Current taxes**

Provision for current tax is made after taking into consideration benefits admissible under provisions of the Income Tax Act, 1961. Minimum Alternative Tax (MAT) credit entitlement is recognized where there is convincing evidence that the same can be realized in future.

### **b. Deferred Taxes**

The deferred tax charge or credit the corresponding deferred tax liabilities or assets are recognized using the tax rates that have been enacted or substantively enacted by the balance sheet date. Deferred tax assets are recognized only to the extent there is reasonable certainty that the assets can be realized in future; however, where there is unabsorbed depreciation or carried forward loss under taxation laws, deferred tax assets are recognized only if there is reasonable certainty of realization of such assets.

For Bio-Medica Laboratories Pvt. Ltd.

  
Director.



For Bio-Medica Laboratories Pvt. Ltd.

  
Director.



**2.11 PROVISIONS, CONTINGENT LIABILITIES, AND CONTINGENT ASSET**

The Company creates a provision when there is a present obligation as a result of past events, and it is probable that there will be outflow of resources and a reliable estimate of the obligation can be made of the amount of the obligation. Contingent liabilities are not recognized but are disclosed in the notes to the financial statements. A disclosure for a contingent liability is made when there is a possible obligation or a present obligation in respect of which the likelihood of outflow of resources is remote.

Provisions are reviewed at each balance sheet date and adjusted to reflect the current best estimate. If it is no longer probable that the outflow of resources would be required to settle the obligation, the provision is reversed.

Contingent assets are neither recognized nor disclosed in the financial statements.

**2.13 CASH AND CASH EQUIVALENTS**

Cash and cash equivalents in the Balance sheet comprise cash at banks and on hand and short-term deposits with an original maturity of three or less month, which are subject to an insignificant risk of changes in value.

**2.14 CASH FLOW STATEMENT**

Cash flows are reported using the indirect method, whereby profit before tax is adjusted for the effects of transactions of a non-cash nature, any deferrals or accruals of past or future operating cash receipts or payments and item of income or expenses associated with investing or financing cash flows. The cash flows from operating, investing and financing activities of the Company are segregated.

**2.15 EARNING PER SHARE****a. Basic earnings per share**

Basic earnings per share is calculated by dividing the profit attributable to owners of the Company by the weighted average number of equity shares outstanding during the financial year, adjusted for bonus element in equity shares issued during the year, if any and excluding treasury shares.

**b. Diluted earnings per share**

Diluted earnings per share adjusted the figures used in the determination of basic earnings per share to take into account the after-income tax effect of interest and other financing costs associated with dilutive potential equity shares, and the weighted average number of additional equity shares that would have been outstanding assuming the conversion of all dilutive potential equity shares.

**2.15 EVENTS AFTER REPORTING DATE**

Where events occurring after the balance sheet date provide evidence of conditions that existed at the end of the reporting period, the impact of such events is adjusted within the financial statements. Otherwise, events after the balance sheet date of material size or nature are only disclosed.

**3. OTHER NOTES TO ACCOUNTS**

3.1 All the Debtors, Creditors, Loans and advances and bank balances have been taken as per books of accounts and are subject to confirmation/reconciliation.

3.2 As per the information on records, the Company have the following dues outstanding to Micro and Small Industries enterprises under MSMED Act, 2006 :-

Particulars	F.Y. 2023-24 Amount (Rs.)	F.Y. 2022-23 Amount (Rs.)
Dues outstanding to Micro and Small Industries enterprises	9,949.40	3,118.98
<b>Total(Rs.)</b>	<b>9,949.40</b>	<b>3,118.98</b>

3.3 Payment to Auditors (exclusive of all applicable taxes)

Particulars	Rupees in thousands	
	F.Y. 2023-24 Amount (Rs.)	F.Y. 2022-23 Amount (Rs.)
Audit Fees	30.00	30.00
<b>Total(Rs.)</b>	<b>30.00</b>	<b>30.00</b>

3.4 Remuneration to Directors

Particulars	Rupees in thousands	
	F.Y. 2023-24 Amount (Rs.)	F.Y. 2022-23 Amount (Rs.)
Remuneration to Directors	4,800.00	4,800.00
<b>Total(Rs.)</b>	<b>4,800.00</b>	<b>4,800.00</b>

For Bio-Medica Laboratories Pvt. Ltd.

*Mulash*  
Director.



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.

3.5 According to AS-18 Related Party Disclosures issued by the Institute of Chartered Accountants of India and specified u/s 133 of the Act read with Rule 7 of the Companies (Accounts) Rule, 2014, there are some relative party transaction the details of which are as under:

Rupees in thousands					
S.No.	Name of Party	Relation	Nature of Transaction	Amount (Rs.) for the year ended 2024	Amount (Rs.) for the year ended 2023
1	Mukesh Mehta	Director of the company	Loan taken	4,600.00	-
2	Mukesh Mehta	Director of the company	Repayment of Loan	5,000.00	12,500.00
3	Pradeep Mehta	Director of the company	Loan taken	2,206.00	1,076.64
4	Pradeep Mehta	Director of the company	Repayment of Loan	1,483.50	5,500.00
5	Mukesh Mehta	Director of the company	Interest on Unsecured Loan taken	735.57	718.89
6	Pradeep Mehta	Director of the company	Interest on Unsecured Loan taken	154.99	309.65
7	Hospira Healthcare	Sister Concern	Sales	28.17	-
8	Tara Mehta	Director's Relative	Salary Paid	420.00	425.00
9	Garima Mehta	Director's Relative	Salary Paid	360.00	360.00
10	Anju Mehta	Director's Relative	Salary Paid	360.00	360.00
11	Lokesh Mehta	Director's Relative	Salary Paid	960.00	960.00
12	Bio Medica Parentals	Sister Concern	Supervision Charges Paid	120.00	120.00
13	Mukesh Mehta	Director of the company	Director's Remuneration	2,400.00	2,400.00
14	Pradeep Mehta	Director of the company	Director's Remuneration	2,400.00	2,400.00
15	Sears Phytochem Pvt Ltd	Sister Concern	Purchases Made	1,772.99	-

3.6 Reporting in respect to Point "Y- Additional Regulatory Information" given in "General Instructions for preparation of Balance Sheet" of Schedule III of Companies Act, 2013 is as under:

- The Company does not have any immovable property (other than properties where the Company is the lessee and the lease agreements are duly executed in favour of the lessee) whose title deeds are not held in the name of the company.
- The Company has not revalued its Property, Plant and Equipment.
- The Company has not granted loans or advances in the nature of loans are granted to promoters, Directors, KMPs and the related parties (as defined under Companies Act, 2013.) either severally or jointly with any other person, that are:
  - repayable on demand or
  - without specifying any terms or period of repayment
- During the year under audit the company does not have any Capital Work in Progress.
- The Company does not have any intangible assets under development.
- No proceedings have been initiated or pending against the company for holding any benami property under the Benami Transactions (Prohibition) Act, 1988 (45 of 1988) and the rules made thereunder.
- The company has taken borrowings from banks or financial institution on the basis of security of current asset, however as it is an overdraft and term loan limit and therefore the company does not required to submit quarterly returns or statements of current assets to the bank as per the terms of sanction.
- The company is not declared as wilful defaulter by any bank or financial institution or other lender.
- The company does not have any transactions with companies struck off under section 248 of the Companies Act, 2013 or section 560 of Companies Act, 1956
- That, the company has created and satisfied the following charges on its properties and assets the details of which are given below, but registrations of which are still pending with the There are charges or satisfaction yet to be registered with Registrar of Companies :-

Serial No.	Brief Description of charge creation and satisfaction	Due date for registration	Closing Balance as on 31.03.2024
1	Kotak Mahindra Bank (LAP-18782388) Limit 220 Lakhs - Creation	10/6/2025	1,57,01,605.00
2	Kotak Mahindra Bank (LAP-19028771) Limit 250 Lakhs - Creation	17/03/2024	2,37,85,901.00
3	Cholamandalam Investment And Finance Company Ltd. - Satisfaction	15/12/2021	-

For Bio-Medica Laboratories Pvt. Ltd.

*Mukesh*  
Director.



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.



xi. The company does not have any investments and hence, compliance with the number of layers prescribed under clause (87) of section 2 of the Act read with Companies (Restriction on number of Layers) Rules, 2017 is not applicable.

xii. Financial Ratios to be disclosed:

Ratios	Numerator	Denominator	Remark	Ratios as at 31.03.2024	Ratios as at 31.03.2023	Percentage Change
Current Ratio	Current Assets	Current Liabilities	In Times	1.66	0.89	86%
Debt Equity Ratio	Debt Capital	Shareholder's Capital	In Times	1.45	1.72	-16%
Debt Service coverage ratio	Earnings available for Debt service	Debt Service	In Times	0.73	0.79	-8%
Return on Equity Ratio	Net Profit After Tax (-) Preference Dividend (if any)	Average Shareholder's Equity	In percentage	26.31	3.6	631%
Inventory Turnover Ratio	Sales	Average Inventory	In Times	2.71	3.72	-27%
Trade Receivables turnover ratio	Net Credit Sales	Average Trade Receivables	In Times	4.76	3.43	40%
Trade payables turnover ratio	Net Credit Purchases	Average Trade Payables	In Times	2.91	3.1	-6%
Net capital turnover ratio	Sales	Working Capital	In Times	3.68	15.02	-76%
Net profit ratio	Net Profit After Tax (-) Preference	Sales	In percentage	0.17	0.02	763%
Return on Capital employed	Earnings Before Interest and Taxes	Capital Employed	In percentage	0.35	0.17	103%
Return on investment	Net Return on Investment	Cost of Investment	In percentage	N/A	N/A	N/A

Reason for variance in the ratios of more than 25% is represented below:

**1) Current Ratio**

That, during the year there has been a significant increase in current assets, resulting in a corresponding rise in the current ratio.

**2) Debt Service Coverage Ratio**

That, during the year there is substantial increase in the profit margin as compared to last year and the earnings available for debt service is high as compared to the last year leads to increase in Debt Service Coverage Ratio.

**3) Return on Equity Ratio**

That, during the year there is substantial increase in the profit margin as compared to last year leads to increase in Return of Equity Ratio. There was no major change in the shareholder's funds, therefore the resulting factor is profit.

**4) Inventory Turnover Ratio**

That, during the fiscal year under review, the company has optimized the utilization of its inventory more effectively compared to the previous year. As a result, there has been a noticeable increase in the inventory turnover ratio.

**5) Trade Receivable Turnover Ratio**

That, during the period under consideration, the company has adopted a slightly more liberal policy for the management and control of trade receivables. As a result, there has been a noticeable increase in the Trade Receivables Turnover Ratio.

**6) Net capital turnover ratio**

That, during the year there is substantial increase in the Working Capital as compared to Sales which leads to increase in Net capital turnover ratio. There was no major change in the other particulars, therefore the resulting change is due to increase in working capital.

**7) Net Profit Ratio**

That, during the fiscal year under review, the company experienced a significant increase in its net profit after tax. This notable growth in net profit has led to a substantial improvement in the net profit margin, reflecting a more favorable financial performance compared to the previous period.

**8) Return on capital employed Ratio**

During the year under consideration there was substantial increase in the profit as compared to capital employed during the year. Therefore, the profit during the year was high leading to variance in the ratio.

For Bio-Medica Laboratories Pvt. Ltd.

*Munish*  
Director.



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.

xiii. There is no Scheme of Arrangements has been approved by the Competent Authority under section 230 to 237 of Companies, Act, 2013.

xiv. A. Company has directly or indirectly neither lend nor invest in any other persons or entities nor provide any guarantee or security on or behalf of ultimate beneficiaries.

B. Company has not received any fund from any person or entities directly or indirectly, lend or invest in any other persons or entities or provide any guarantee or security on or behalf of ultimate beneficiaries.

3.7 It may be noted that some figures in the schedule may be reflected as nil, but in actuality the figures exist and due to rounding off in thousands, the amount being immaterial is not shown.

3.8 Disclosure of CSR Activities as per Sec. 135

Note : During the current year, the company did not meet the criteria specified under section 135(1) of the Companies Act, 2013, read along with the Companies (Corporate Social Responsibility Policy) Amendment Rules, 2022, hence it was not required to carry out any CSR activities. Additionally, there were no CSR expenses incurred in the previous year.

3.9 Indications of Impairment- In the opinion of management, there are no indications, internal or external which could have the effect of impairing the value of assets to any material extent as at the Balance sheet date requiring recognition in terms of AS 28

3.10 Company has not traded or invested in Crypto currency or virtual currency during the financial year, hence reporting under this point is not applicable to the company.

3.11 Previous year's figure have been regrouped & rearranged wherever necessary to make them comparable.

AS PER OUR REPORT ATTACHED

For SATYANARAYAN CHANDRAKANT LLP  
Chartered Accountants

(CA) Prashant Goyal Partner  
MEN: 429701  
PIN: 00603672 C400008  
Indore: 22-08-2024  
UDIN: 24429306-000000582

BIO MEDICA LABORATORIES PRIVATE LIMITED

(CIN: U24230MP2015PTC034576)

Mukesh Mehta  
Director  
DIN: 05187420

Pradeep Mehta  
Director  
DIN: 07254802

For Bio-Medica Laboratories Pvt. Ltd.

Mukesh Mehta  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

Pradeep Mehta

Director.



<p style="text-align: center;">BIO MEDICA LABORATORIES PRIVATE LIMITED PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015 CIN: U24230MP2015PTC034576</p> <p style="text-align: center;">BALANCE SHEET AS AT 31.03.2024</p> <p style="text-align: right;">Rupees in thousands</p>			
PARTICULARS	Note No	AMOUNT(Rs.) AS AT 31.03.2024	AMOUNT(Rs.) AS AT 31.03.2023
<b>I. EQUITY AND LIABILITIES</b>			
(a) Share Capital	4	1,000.00	1,000.00
(b) Reserves and Surplus	5	52,447.64	26,133.88
(c) Money received against share warrants		-	-
(2) Share application money pending allotment		-	-
<b>(3) Non-Current Liabilities</b>			
(a) Long-term borrowings	6	77,657.86	46,704.76
(b) Deferred tax liabilities (Net)		-	-
(c) Other Long term liabilities		-	-
(d) Long term provisions		-	-
<b>(4) Current Liabilities</b>			
(a) Short-term borrowings	7	27,241.50	49,361.88
(b) Trade Payables		-	-
(A) Total outstanding dues of micro enterprises and small enterprises		9,949.40	3,118.98
(B) Total outstanding dues of creditors other than micro enterprises and small enterprises		11,645.47	44,860.82
(c) Other current liabilities	8	925.76	1,289.14
(d) Short-term provisions	9	13,083.52	2,934.72
<b>Total (Rs.)</b>		<b>1,93,951.15</b>	<b>1,75,404.19</b>
<b>II. ASSETS</b>			
<b>(1) Non-current assets</b>			
(a) Property, Plant & Equipment and Intangible assets	10	87,271.59	83,114.70
(i) Property, Plant & Equipment		-	-
(ii) Intangible assets		-	-
(iii) Capital work-in-progress		-	-
(iv) Intangible assets under development		-	-
(b) Non-current investments		-	-
(c) Deferred tax assets (net)	11	1,083.80	259.78
(d) Long term loans and advances		-	-
(e) Other non-current assets	12	1,309.21	3,190.63
<b>(2) Current assets</b>			
(a) Current investments		-	-
(b) Inventories	13	73,668.60	39,019.19
(c) Trade receivables	14	23,358.80	40,731.21
(d) Cash and cash equivalents	15	103.24	61.38
(e) Short-term loans and advances	16	2,100.58	2,406.36
(f) Other current assets	17	5,055.34	6,620.94
<b>Total (Rs.)</b>		<b>1,93,951.15</b>	<b>1,75,404.19</b>
AS PER OUR REPORT ATTACHED		FOR AND ON BEHALF OF THE BOARD OF DIRECTORS OF	
For SATYANARAYAN ACCOUNTANTS & CO LLP		BIO MEDICA LABORATORIES PRIVATE LIMITED	
Chartered Accountants		(CIN: U24230MP2015PTC034576)	
(CA. Prakash Goyal) Partner		Mukesh Mehta	Pradeep Mehta
MRN: 430700		Director	Director
ERN: 006636C/ C400333		DIN: 03187420	DIN: 07254802
Indore: 22.08.2024			
UDIN: 24429700BKCQNM4582			

For Bio-Medica Laboratories Pvt. Ltd.

*Mukesh Mehta*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*Pradeep Mehta*


Director.

BIO MEDICA LABORATORIES PRIVATE LIMITED PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015 CIN: U24230MP2015PTC034576 STATEMENT OF PROFIT & LOSS FOR THE YEAR ENDED 31.03.2024			
PARTICULARS		Rupees in thousands	
	Note No	AMOUNT (Rs.) AS ON 31.03.2024	AMOUNT (Rs.) AS ON 31.03.2023
I. Revenue from operations	18	1,52,493.56	1,62,281.78
II. Other Income	19	948.71	492.90
III. Total Income (I + II)		1,53,442.29	1,62,774.68
IV. Expenses:			
Cost of materials consumed	20	73,821.31	1,15,870.74
Purchases of Stock-in-Trade		-	-
Changes in inventories of finished goods, work-in-progress and Stock-in-Trade	21	(7,123.44)	(1,189.24)
Employee benefits expense	22	17,033.99	18,123.09
Financial costs	23	9,659.10	7,742.70
Depreciation and amortization expense	10	11,099.64	4,966.77
Other expenses	24	13,256.21	12,383.95
Total Expenses		1,17,796.81	1,57,896.01
V. Profit before exceptional and extraordinary items and tax	(III - IV)	35,695.49	4,876.67
VI. Exceptional items		-	-
VII. Profit before extraordinary items and tax (V - VI)		35,695.49	4,876.67
VIII. Extraordinary items		-	-
IX. Profit before tax (VII - VIII)		35,695.49	4,876.67
X. Tax expense:			
(1) Current tax		10,218.38	1,257.07
(2) Deferred tax liability/(assets)	7	(824.02)	21.01
XI. Profit/(Loss) for the period from continuing operations	(VII-VIII)	26,301.13	3,598.59
XII. Profit/(Loss) from discontinuing operations		-	-
XIII. Tax expense of discontinuing operations		-	-
XIV. Profit/(Loss) from Discontinuing operations (after tax)	(XII - XIII)	-	-
XV. Profit/(Loss) for the period	(XI + XIV)	26,301.13	3,598.59
XVI. Excess/(Short) Provision Made Last Year (Income Tax)		12.63	-
XVII. Profit of the Year		26,313.76	3,598.59
Profit Forward to Reserve & Surplus		26,313.76	3,598.59
XVIII. Earnings per equity share (in Rs.)			
(1) Basic		263.14	35.99
(2) Diluted		263.14	35.99
AS PER OUR REPORT ATTACHED		FOR AND ON BEHALF OF THE BOARD OF DIRECTORS OF	
For SATYANARAYAN GOYAL & CO. Chartered Accountants (CA. Prakash Goyal) Partner MRN: 429700 FRN: 006636C/ C400333 Indore: 22.03.2024 UDIN: 24429700BKCQNM4582		BIO MEDICA LABORATORIES PRIVATE LIMITED (CIN: U24230MP2015PTC034576)  Mukesh Mehta Director DIN: 03187420	
		 Pradeep Mehta Director DIN: 07254802	

For Bio-Medica Laboratories Pvt. Ltd.

  
Director.

For Bio-Medica Laboratories Pvt. Ltd.



Director.

**BIO MEDICA LABORATORIES PRIVATE LIMITED**  
**PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015**  
**CIN: U24230MP2015PTC034576**

**CASH FLOW STATEMENT FOR THE YEAR ENDED ON 31.03.2024**

Particulars	Rupees in thousands	
	Amount (Rs.) 31.03.2024	Amount (Rs.) 31.03.2023
Net Profit before tax from Continuing Operations	35,695.49	4,876.67
<b>1. Cash Flow from Operating Activities</b>		
<u>Non Cash adjustment</u>		
Financing Activities	9,659.10	7,742.70
Excess IT Provision Made Last Year	12.63	-
Depreciation	11,099.64	4,966.77
Income Tax Provision for the Year	(10,218.38)	(1,257.07)
<b>Operating Profit before Working Capital Changes</b>	<b>56,466.86</b>	<b>9,843.44</b>
<b>Movement in Working Capital</b>		
Changes from Short term Borrowings	(22,120.38)	(19,043.57)
Changes in Trade Payable	(26,384.93)	11,818.90
Changes in Other current Liabilities	(363.38)	(1,846.04)
Changes in Short term Provisions	10,148.81	825.59
Change in Current Investments	-	-
Changes in Inventory	(34,649.41)	(15,742.72)
Changes in Trade Receivables	17,372.41	13,737.92
Changes in Other Current assets	305.79	705.10
Changes in Short term Loans & Advances	1,565.59	(268.11)
Taxes Paid	-	-
<b>Net cash flow from Operating Activities (1)</b>	<b>(54,125.50)</b>	<b>(9,812.93)</b>
<b>2. Cash Flow from Investing Activities</b>		
Purchase of Fixed assets	(15,256.53)	(17,095.92)
Sale of Assets	-	-
Increase in Long Term Loans and Advances	-	-
Increase in Non current assets	1,881.42	2,759.11
<b>Net cash flow from Investing Activities (2)</b>	<b>(13,375.11)</b>	<b>(14,336.81)</b>
<b>3. Cash Flow from Financing Activities</b>		
Proceeds from long term borrowings	30,953.10	5,505.52
Interest on borrowed capital	(9,659.10)	(7,742.70)
<b>Net cash flow from Financing Activities (3)</b>	<b>21,294.00</b>	<b>(2,237.18)</b>
<b>Net Cash flows (1+2+3)</b>	<b>41.86</b>	<b>(10,067.85)</b>
<b>Cash and Cash Equivalent at the beginning of the year</b>	<b>61.38</b>	<b>10,119.23</b>
<b>Cash and Cash Equivalent at the End of the year</b>	<b>103.24</b>	<b>61.38</b>
<b>Component of Cash and Cash Equivalents</b>		
Cash in hand	101.23	38.36
Bank Balance	2.01	23.02

AS PER OUR REPORT ATTACHED

For: SATYANARAYAN GOXAL & CO. LLP

(Chartered Accountants)

FRN: 006366 C-400283

(CA. Pooja Goyal) Partner

MRN: 429300

UDIN: 244 297008 REC-14582

Indore: 22.08.2024

FOR AND ON BEHALF OF THE BOARD OF DIRECTORS OF

BIO MEDICA LABORATORIES PRIVATE LIMITED

(CIN: U24230MP2015PTC034576)

Mukesh Mehta

Director

DIN: 03187420

Pradeep Mehta

Director

DIN: 07254802

For Bio-Medica Laboratories Pvt. Ltd.

*Mukesh Mehta*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*Pradeep Mehta*  
Director.



**BIO MEDICA LABORATORIES PRIVATE LIMITED**  
PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS ON 31.03.2024**

Rupees in thousands

PARTICULARS	AMOUNT (Rs.) 31.03.2024	AMOUNT (Rs.) 31.03.2023
<b>NOTE- 4</b>		
<b>SHARE CAPITAL</b>		
a) Authorised Share Capital		
Equity Shares of Rs.10 each		
100000 Equity Shares of Rs. 10 each	1,000.00	1,000.00
	1,000.00	1,000.00
b) Issued Subscribed & Paid up Capital		
100000 Equity Shares of Rs. 10 each	1,000.00	1,000.00
<b>Total (Rs.)</b>	<b>1,000.00</b>	<b>1,000.00</b>

**4.1 Ternyrights attached to the Equity Share :-**

The company has only one class of Equity Shares having a par value of Rs. 10/- per share. Each holder of Equity share is entitled to one vote per share. In the event of liquidation of the Company, the holders of equity share will be entitled to receive remaining assets of the Company, after distribution of all preferential amounts. The distribution will be in proportion to the number of equity shares held by the Share holders.

**4.2 Details of shares held by each shareholder holding more than 5% shares:**

Class of shares / Name of shareholder	As at 31.03.2024		As at 31.03.2023	
	Number of shares held	% holding	Number of shares held	% holding
Equity shares with voting rights				
Pradeep Mehta	50,000	50%	50,000	50%
Mukesh Mehta	50,000	50%	50,000	50%

**4.3 Details of shares held by Promoters**

Sr. No.	Name of the Promoter	As at 31.03.2024		As at 31.03.2023	
		Number of shares held	% holding	Number of shares held	% holding
1	Pradeep Mehta	50,000	50%	50,000	50%
2	Mukesh Mehta	50,000	50%	50,000	50%

**4.4 Percentage Change of Shares held by promoters during the year**

Sr. No.	Name of the Promoter	As at 31.03.2024	As at 31.03.2023



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*  
Director.



**BIO MEDICA LABORATORIES PRIVATE LIMITED**  
PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS ON 31.03.2024**

Rupees in thousands

PARTICULARS	AMOUNT (Rs.) 31.03.2024	AMOUNT (Rs.) 31.03.2023
<b>NOTE-5</b>		
<b>RESERVES &amp; SURPLUS</b>		
a) Surplus / (Deficit) in Statement of Profit and Loss		
Opening Balance	26,133.88	22,535.29
Add: Profit / (Loss) for the year	26,313.76	3,598.59
Closing Balance	52,447.64	26,133.88
<b>Total (Rs.)</b>	<b>52,447.64</b>	<b>26,133.88</b>
<b>NOTE-6</b>		
<b>LONG TERM BORROWINGS</b>		
Secured		
Kotak Mahindra Bank (LAP-18400788)	11,571.41	12,618.08
Kotak Mahindra Bank (LAP-18312485)	8,958.96	10,048.61
Kotak Mahindra Bank (LAP-18107771)	5,878.13	6,839.63
Kotak Mahindra Bank (LAP-19028771)	23,785.90	-
Kotak Mahindra Bank (LAP-18782388)	15,701.61	-
Kotak Mahindra Bank (5933CL0100000119)	5,409.80	5,442.53
Kotak Mahindra Bank (5933TL0100000400)	5,124.62	6,019.07
Kotak Mahindra Bank (5933TL0100000403)	1,227.42	2,952.71
ICICI Bank (Car Loan - Baleno)	-	10.63
ICICI Bank (Truck Loan - Tata Ace)	-	-
Kotak Mahindra Bank (Bank Loan - 30 Lakhs)	-	431.89
Kotak Mahindra Bank (Bank Loan - 33 Lakhs)	-	413.20
Kotak Mahindra Bank (Machinery Loan)	-	-
MSME Loan	-	678.42
SEDBI Loan - 7000000	-	1,250.00
<b>Total (Rs.)</b>	<b>77,657.86</b>	<b>46,704.76</b>

**Details of Securities and terms of repayment**

Sr. No.	Loan Particulars	Nature Of Security	Terms of Repayment
1	Kotak Mahindra Bank (LAP-18400788)	Secured by Hypothecation/mortgage of property and assets acquired out of this loan	120 months from the date when the loan was taken initially.
2	Kotak Mahindra Bank (LAP-18312485)	Secured by Hypothecation/mortgage of property and assets acquired out of this loan	120 months from the date when the loan was taken initially.
3	Kotak Mahindra Bank (LAP-18107771)	Secured by Hypothecation/mortgage of property and assets acquired out of this loan	120 months from the date when the loan was taken initially.
4	Kotak Mahindra Bank (LAP-19028771)	Secured by Hypothecation/mortgage of property and assets acquired out of this loan	144 months from the date when the loan was taken initially.
5	Kotak Mahindra Bank (LAP-18782388)	Secured by Hypothecation/mortgage of property and assets acquired out of this loan	120 months from the date when the loan was taken initially.
6	Kotak Mahindra Bank (5933CL0100000119)	Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee	60 months from the date when the loan was taken initially.
7	Kotak Mahindra Bank (5933TL0100000400)	Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee	84 months from the date when the loan was taken initially.
8	Kotak Mahindra Bank (5933TL0100000403)	Secured by Hypothecation/mortgage of assets acquired out of this loan and other fixed assets of the company and personal guarantee	36 months from the date when the loan was taken initially.



For Bio-Medica Laboratories Pvt. Ltd.

*Murthy*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.

**BIO MEDICA LABORATORIES PRIVATE LIMITED**  
PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS ON 31.03.2024**

<b>NOTE-7</b>		
<b>SHORT TERM BORROWINGS</b>		
Secured		
a) Loans Repayable on Demand		
From Banks		
Kotak Mahindra Bank (BPCA A/c -8905)	6,965.09	29,993.32
b) Current Maturities of Long Term Borrowings	9,907.13	12,034.24
Unsecured		
a) Loans From Directors & their Relatives :-		
Mukesh Mehta	6,936.03	6,747.38
Pradeep Mehta	1,433.24	586.75
Lokesh Mehta	2,000.00	-
<b>Total (Rs.)</b>	<b>27,241.50</b>	<b>49,361.88</b>

<b>Details of Securities</b>		
Sr. No.	Loan Particulars	Nature Of Security
1	Overdraft Facility	Secured by Hypothecation/ mortgage of current assets.

<b>NOTE-TRADE PAYABLES</b>					
For the year ended 31.03.2024					
Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	9,748.79	166.62	34.00	-	9,949.41
Others	11,619.41	1.06	-	25.00	11,645.47
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
<b>Total</b>	<b>21,368.20</b>	<b>167.68</b>	<b>34.00</b>	<b>25.00</b>	<b>21,594.88</b>

For the year ended 31.03.2023					
Particulars	Outstanding for following periods from due date of payment				Total
	Less than 1 Year	1-2 Years	2-3 Years	More than 3 Years	
MSME	3,118.98	-	-	-	3,118.98
Others	44,401.35	364.89	25.38	69.20	44,860.82
Dispute dues-MSME	-	-	-	-	-
Dispute dues	-	-	-	-	-
Others	-	-	-	-	-
<b>Total</b>	<b>47,520.33</b>	<b>364.89</b>	<b>25.38</b>	<b>69.20</b>	<b>47,979.80</b>

<b>NOTE-8</b>		
<b>OTHER CURRENT LIABILITIES</b>		
a) Advances received from customers	587.53	982.47
b) Creditors for Capital Goods	35.20	32.95
c) Creditors for Expenses	305.04	273.71
<b>Total (Rs.)</b>	<b>925.77</b>	<b>1,289</b>

<b>NOTE-9</b>		
<b>SHORT TERM PROVISIONS</b>		
A) Provision for Tax		
Provision for Income Tax(Current Years)	10,218.38	1,257.07
TDS Payable	247.32	350.62
B) Provision- Others		
Electricity Bill Payable	432.85	291.33
Salary Payable	1,967.45	926.77
Provision for Gratuity ( Current)	172.49	-
Audit Fees Payable	30.00	85.00
ESIC Payable	2.91	3.77
PF Payable	11.67	16.16
GST RCM Payable	0.47	4.00
<b>Total (Rs.)</b>	<b>13,083.54</b>	<b>2,934.72</b>

For Bio-Medica Laboratories Pvt. Ltd.

*Mukesh Mehta*  
Director.



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.

**BIO MEDICA LABORATORIES PRIVATE LIMITED**  
PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS ON 31.03.2024**

<b>NOTE-10</b>						
<b>ANNEXURE "A"</b>						
<b>PROPERTY, PLANT, EQUIPMENT AND INTANGIBLE ASSETS</b>						
As per separate sheet attached						
<b>Total (Rs.)</b>				87,271.59	83,114.70	
<b>Total (Rs.)</b>				87,271.59	83,115	
<b>NOTE-11</b>						
<b>DEFERRED TAX LIABILITIES (NET)</b>						
Deferred Tax Liability as at the Commencement of the year				259.78	280.79	
Add: Deferred Tax Liability generated during the year				824.02	(21.01)	
<b>Total (Rs.)</b>				1,083.80	259.78	
<b>NOTE-12</b>						
<b>OTHER NON-CURRENT ASSETS</b>						
LPG Deposit				* 8.50	8.50	
MPES Deposit				683.26	723.56	
Miscellaneous Deposit				33.01	33.01	
Piped Natural Gas				501.00	501.00	
SEDBI Deposit				83.44	1,924.56	
<b>Total (Rs.)</b>				1,309.21	3,190.63	
<b>NOTE-13</b>						
<b>INVENTORIES</b>						
Raw Material				10,093.89	10,077.11	
Work-in-Progress				3,464.54	1,074.46	
Finished Goods				9,703.18	4,969.82	
Packing Material				50,467.00	22,897.81	
<b>Total (Rs.)</b>				73,668.61	39,019.20	
<b>NOTE-14</b>						
<b>TRADE RECEIVABLES</b>						
For the year ended 31.03.2024						
Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months-1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables-Considered Goods	21,026.81	961.19	1,167.26	-	2.07	23,157.33
Undisputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables-Considered Goods	-	-	-	-	201.47	201.47
Disputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-
<b>Total</b>	<b>21,026.81</b>	<b>961.19</b>	<b>1,167.26</b>	<b>-</b>	<b>203.54</b>	<b>23,358.80</b>



For Bio-Medica Laboratories Pvt. Ltd.

*Hitesh*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.



BIO MEDICA LABORATORIES PRIVATE LIMITED  
PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015

NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS ON 31.03.2024

For the year ended 31.03.2023

Particulars	Outstanding for following periods from due date of payment					Total
	Less than 6 Months	6 Months -1Year	1-2 Years	2-3 Years	More than 3 Years	
Undisputed Trade Receivables-Considered Goods	37,997.05	1,162.51	1,331.68	5.84	234.13	40,731.21
Undisputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Disputed Trade Receivables-Considered Goods	-	-	-	-	-	-
Disputed Trade Receivables-Considered Doubtful	-	-	-	-	-	-
Others	-	-	-	-	-	-
<b>Total</b>	<b>37,997.05</b>	<b>1,162.51</b>	<b>1,331.68</b>	<b>5.84</b>	<b>234.13</b>	<b>40,731.21</b>

**NOTE-15**

**CASH AND CASH EQUIVALENTS**

a) Balance with Bank

Kotak Mahindra Bank - 7911918929

2.01 23.02

b) Cash on hand

(As certified by the Director of the company)

101.23 38.36

**Total (Rs.)** 103.24 61.38

**NOTE-16**

**SHORT TERM LOANS & ADVANCES**

Advances given to Suppliers

2,100.58 2,406.36

**Total (Rs.)** 2,100.58 2,406.36

**NOTE-17**

**OTHER CURRENT ASSETS**

Advance Tax Paid

1,500.00 1,600.00

TDS Receivable AY 2024-25

99.54 48.92

IT Refund Receivables AY 2023-24

404.47 -

Goods and Service Tax (Net)

3,031.73 4,972.02

Other Advances

19.60

**Total (Rs.)** 5,055.34 6,620.94

**NOTE-18**

**REVENUE FROM OPERATION**

Sale of Manufacturing Products (Net of Taxes)

1,44,293.58 1,55,985.78

Sale of Trading Goods (Net of Taxes)

8,200.01 6,296.01

**Total (Rs.)** 1,52,493.58 1,62,281.78

**NOTE-19**

**OTHER INCOME**

Interest Income

78.76 208.03

Discount, Rabate & Rate Difference

219.96 6.34

Receipt from Insurance

- 278.53

Supervision income

650.00 -

**Total (Rs.)** 948.72 492.90



For Bio-Medica Laboratories Pvt. Ltd.

*Mulash*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.

BIO MEDICA LABORATORIES PRIVATE LIMITED  
PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015

NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS ON 31.03.2024

**NOTE- 20**

**COST OF MATERIAL CONSUMED**

<b><u>Raw Material</u></b>		
Opening Stock of Raw Material	10,077.11	7,360.03
Add: Purchase during the year of:	32,541.24	43,947.02
	42,618.34	51,307.05
Less: Closing Stock	10,033.89	10,077.11
Raw Material Consumed (A)	32,584.45	41,229.94
<b><u>Packing Material</u></b>		
Opening Stock of Packing Material	22,897.81	11,061.41
Add: Purchase during the year of:	68,806.04	86,477.20
	91,703.85	97,538.61
Less: Closing Stock	50,467.00	22,897.81
Packing Material Consumed (B)	41,236.85	74,640.80
<b>Total (Rs.)</b>	<b>73,821.31</b>	<b>1,15,870.74</b>

**NOTE- 21**

**CHANGES IN INVENTORIES OF FINISHED GOODS, WORK-IN-PROGRESS AND STOCK-IN-TRADE**

Closing Stock at the beginning of the year		
Work-in-progress	1,074.46	231.56
Finished Goods	4,969.82	4,623.47
Closing Stock at the end of the year		
Work-in-progress	3,464.54	1,074.46
Finished Goods	9,703.18	4,969.82
<b>NET INCREASE/(DECREASE) (Rs.)</b>	<b>(7,123.44)</b>	<b>(1,189.24)</b>

**NOTE- 22**

**EMPLOYEE BENEFIT EXPENSES**

Salaries & Wages	11,269.24	17,340.27
Bonuses	574.68	518.50
Contribution to provident fund and other funds	217.59	248.02
Labour Welfare	-	16.30
Remuneration to directors	4,800.00	-
Gratuity Expenses	172.49	-
<b>Total (Rs.)</b>	<b>17,034.00</b>	<b>18,123.09</b>

**NOTE- 23**

**FINANCIAL COSTS**

<b>a) Interest Expenses</b>		
Interest on Bank Loans	8,490.68	6,249.38
Interest on Others Loans	890.56	1,045.97
<b>b) Other Borrowing Cost</b>		
Loan Processing Charges	276.31	437.50
Bank Charges	1.55	9.86
<b>Total (Rs.)</b>	<b>9,659.10</b>	<b>7,742.71</b>



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.

**BIO MEDICA LABORATORIES PRIVATE LIMITED**  
PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015

**NOTES FORMING PART OF THE FINANCIAL STATEMENTS AS ON 31.03.2024**

<b>NOTE- 24</b>		
<b><u>OTHER EXPENSES</u></b>		
Electricity Expenses	4,888.72	3,623.56
Freight & Transportation Expenses	587.91	2,160.39
Power & Fuel	3,151.48	2,589.96
Repair & Maintenance	723.71	1,023.48
Supervision Charges	120.00	120.00
Manufacturing & Testing Expenses	216.26	212.55
Commission Paid	210.53	385.19
Office & Factory Expenses	334.17	190.03
Travelling Expenses	122.71	169.07
Design Charges	176.60	70.76
Insurance Expenses	1,339.10	256.28
Lease Rent & Factory License	131.32	136.36
Legal & Professional Expense	66.60	285.25
Exchange Rate Diff	-	3.21
GST demand	30.77	-
Import Charges and Carriage	415.07	-
Miscellaneous Expenses	274.16	446.32
Late Fees, Interest & Penalties	-	1.14
License Fees	-	190.98
Printing & Stationary	91.54	75.40
Property tax	47.71	299.74
Packaging expenses	161.40	-
Telephone Expenses	22.36	23.19
Vehicle Expenses	114.09	91.08
Consultancy Fees	5.00	5.00
Audit Fees	25.00	25.00
<b>Total (Rs.)</b>	<b>13,256.21</b>	<b>12,383.94</b>



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.



## ANNEXURE "A" of note No.10

BIO MEDICA LABORATORIES PRIVATE LIMITED  
PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015  
CIN: U24230MP2015PTC034576

## NOTES TO THE FINANCIAL STATEMENT FOR THE YEAR ENDED 31.03.2024

## DEPRECIATION SCHEDULE AS PER COMPANIES ACT, 2013

Particulars	RATE OF DEPN.	GROSS BLOCK			DEPRECIATION			NET BLOCK	
		BALANCE AS ON 01.04.2023	ADDITION OR (DEDUCTION)	TOTAL AS ON 31.03.2024	BALANCE AS ON 01.04.2023	FOR THE YEAR	TOTAL AS ON 31.03.2024	AS ON 31.03.2024	AS ON 31.03.2023
<b>a) Tangible Assets</b>									
Immovable Assets -									
Leasehold Land & Building - Unit I	9.50%	5,829.33	-	5,829.33	3,608.09	211.02	3,819.11	2,010.22	2,221.24
Leasehold Land & Building - Unit II	9.50%	41,951.98	1,482.54	43,434.52	499.22	3,999.08	4,498.30	38,936.22	41,452.77
Leasehold Land & Building - Unit III	9.50%	-	5,924.62	5,924.62	-	-	-	5,924.62	-
Plant & Machinery -									
'Plant & Machinery Unit I	13.91%	21,475.66	1,443.06	22,918.73	9,615.21	1,822.03	11,437.23	11,481.49	11,860.46
'Plant & Machinery - Unit II	13.91%	23,580.89	6,316.65	29,897.53	1,019.53	3,671.74	4,691.27	25,206.26	22,561.35
Furnitures & Fixtures -									
'Furniture & Fixtures Unit I	25.89%	990.38	15.17	945.55	616.76	84.80	701.56	243.99	313.62
'Furniture & Fixtures Unit II	25.89%	675.75	-	675.75	81.62	153.82	235.44	440.31	594.13
Other Assets									
Lab Equipments Unit I	25.89%	352.48	-	352.48	180.22	44.60	224.82	127.66	172.26
Lab Equipments - Unit II	25.89%	2,142.43	-	2,142.43	269.94	484.79	754.73	1,387.70	1,872.49
Computers & Data Processing Unit I	63.16%	943.06	-	943.06	801.86	89.18	891.04	52.02	141.20
Computers & Data Processing Unit - II	63.16%	47.46	-	47.46	14.62	20.74	35.36	12.10	32.84
Electric Installations	25.89%	1,453.52	74.49	1,528.01	183.49	356.73	540.23	987.79	1,270.03
Motor Vehicles	25.89%	3,011.22	-	3,011.22	2,388.90	161.12	2,550.02	461.20	622.31
<b>TOTAL (Rs.) - A</b>		<b>1,02,394.16</b>	<b>15,256.53</b>	<b>1,17,650.69</b>	<b>19,279.46</b>	<b>11,099.64</b>	<b>30,379.10</b>	<b>87,271.59</b>	<b>83,114.69</b>
<b>b) Intangible Assets</b>									
<b>TOTAL (Rs.) - B</b>									
<b>GRAND TOTAL (Rs.) A+B</b>		<b>1,02,394.16</b>	<b>15,256.53</b>	<b>1,17,650.69</b>	<b>19,279.46</b>	<b>11,099.64</b>	<b>30,379.10</b>	<b>87,271.59</b>	<b>83,114.69</b>



For Bio-Medica Laboratories Pvt. Ltd.

Director.

For Bio-Medica Laboratories Pvt. Ltd.

Director.

**ANNEXURE "A" of note No.10**

**BIO MEDICA LABORATORIES PRIVATE LIMITED**  
**PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015**  
**CIN: U24230MP2015PTC034576**

**NOTES TO THE FINANCIAL STATEMENT FOR THE YEAR ENDED 31.03.2024**

**DEPRECIATION SCHEDULE AS PER COMPANIES ACT, 2013**

**PREVIOUS YEAR FIGURES**

Particulars	RATE OF DEPN.	GROSS BLOCK			DEPRECIATION			NET BLOCK	
		BALANCE AS ON 01.04.2022	ADDITION OR (DEDUCTION)	TOTAL AS ON 31.03.2023	BALANCE AS ON 01.04.2022	FOR THE YEAR	TOTAL AS ON 31.03.2023	AS ON 31.03.2023	AS ON 31.03.2022
TOTAL (Rs.)		8,228.24	17,095.92	1,02,394.16	14,312.69	4,966.77	19,279.46	83,114.70	7,098.55



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director,

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director,

BIO MEDICA LABORATORIES PRIVATE LIMITED  
PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015  
CIN: U24230MP2015PTC034576

NOTES TO THE FINANCIAL STATEMENT FOR THE YEAR ENDED 31.03.2024

ANNEXURE - I DEPRECIATION AS PER INCOME TAX ACT, 1961

ASSET	OF DEPN.	BALANCE AS ON 01.04.2023	ADDITION		DELETION /SALE	TOTAL	DEPN. FOR THE YEAR	BALANCE AS ON 31.03.2024
			BEFORE 02.10.2023	AFTER 02.10.2023				
Land & Building	10%	15,115.42	-	7,407.16	-	22,522.58	1,881.90	20,640.68
Land & Building	40%	97.22	-	-	-	97.22	38.89	58.33
Plant & Machinery	15%	31,629.38	5,993.17	1,786.03	-	39,408.58	5,777.33	33,631.24
Plant & Machinery	40%	251.31	-	-	-	251.31	100.52	150.79
Furniture & Fittings	10%	1,246.59	70.17	-	-	1,316.76	131.68	1,185.08
TOTAL		48,359.92	6,063.34	9,193.19	-	63,596.45	7,930.32	55,666.12



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.



**BIO MEDICA LABORATORIES PRIVATE LIMITED**  
**PLOT-254, SECTOR-F SANWER ROAD, Indore, (M.P.) - India, 452015**  
**CIN: U24230MP2015PTC034576**

**A. CALCULATION OF DEFERRED TAX LIABILITY / (ASSET)**

Particulars	AMOUNT (Rs.) 31.03.2024	AMOUNT (Rs.) 31.03.2023
Depreciation as per Companies Act, 2013 charged in the books	11,099.64	4,966.77
Depreciation allowable as per Income Tax Act, 1961	7,930.32	5,047.60
<b>Difference</b>	<b>(3,169.32)</b>	<b>80.83</b>

Since Dep. as per comp. act is more than dep. as per income tax therefore, D.T.A. will be increased.

**D.T.L. @ 26%**

**(824.02)**

**21.02**



For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*  
Director.

For Bio-Medica Laboratories Pvt. Ltd.

*[Signature]*

Director.